Contacts

MedinCell announces fiscal year consolidated results April 2020 – March 2021

June 16, 2021

Income from ordinary activities: €11.8 million (+96% compared to the previous year)
Operating expenses: €27.1 million (+8%)
Cash consumption from operations: €12.1 million
Available cash: €47.1 million + €3.9 million of non-risky financial assets
Estimated financial visibility until summer 2023


Key developments of the product portfolio over the period April 2020-March 2021
• Following the announcement of positive results for the Phase 3 trial of mdc-IRM / TV46000 (schizophrenia) in January 2021, Teva Pharmaceuticals, which is leading and funding the program, is preparing for the U.S. regulatory filing, which is expected in mid-2021.
• Expected by the end of 2021, the findings of the ongoing analysis of the results of the first-in-human study of mdc-TJK, the second program in partnership with Teva Pharmaceuticals, will drive future developments.
• End of the Phase 2 clinical trial of mdc-CWM (post-operative pain and inflammation), developed with AIC. Our partner plans to launch new safety and efficacy clinical studies (Phase 3) in 2021.
• Selection of candidate formulations and entry into regulatory development of four new products: mdc-WWM (contraception), mdc-GRT (organ transplant), mdc-KPT (pain/animal health) and mdc-TTG (prophylaxis against Covid-19 and its variants).
• Post-closing: the company announced on June 15, 2021 the selection of a candidate formulation for the mdc-STM (malaria) program supported by the international health agency Unitaid, paving the way for the launch of pre-clinical activities.

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.